In 2010, BELLUS Health entered into a sale and license agreement with global private equity firm Auven Therapeutics for the worldwide rights to KIACTATM in exchange for an upfront fee and revenue sharing.

Auven Therapeutics is currently evaluating whether to further pursue the development of KIACTA™ for the treatment of patients suffering from active pulmonary sarcoidosis. Auven Therapeutics has developed a clinical Phase 2/3 study protocol to evaluate the safety and efficacy of KIACTA™ in pulmonary sarcoidosis. The U.S. Food and Drug Administration has cleared the investigational new drug application (IND) for this clinical Phase 2/3 study.

Sarcoidosis is a rare condition that causes patches of red and swollen tissue - called granulomas - that can develop in multiple organs in the body, but mostly in the lungs and skin. There is no cure for chronic pulmonary sarcoidosis, and treatment options are limited and can have serious adverse effects.

 

Share this

Sign up for email alerts

Email Address *
 
Enter the code shown above.